Megan Garlapow, PhD

All articles by Megan Garlapow, PhD

• Targeted care reduced rate of brain bleeds in newborns

  Neuroprotection bundles, including proper positioning, pain management and respiratory support, can help prevent IVH.

• Study: COVID-19 during pregnancy did not increase risk of complications

  COVID-19 infection at any stage of pregnancy did not lead to worse health outcomes for mothers or infants in a recent study in China.

• Understanding the risks of post-transfusion purpura in infants

  Posttransfusion purpura is a rare but serious immune response that can lead to severe platelet loss and bleeding.

• Case of delayed thrombocytopenia in infant possibly linked to breastfeeding

  In a recent case study, maternal antibodies likely transferred through breastfeeding caused delayed thrombocytopenia in a newborn.

• Newborn becomes first documented patient to have both HDFN and FNAIT

  Genetic and antibody testing in a newborn resulted in dual diagnoses of HDFN and FNAIT, which required prompt, coordinated treatment.

• Genetic insights could help prevent fetal intracranial hemorrhage

  A recent study showed that fetal intracranial hemorrhages often involve a wide array of genetic abnormalities beyond known mutations.

• Rallybio’s potential FNAIT treatment enters phase 2 trial

  A Phase 2 clinical trial is underway to evaluate the safety and pharmacokinetics of RLYB212, a monoclonal antibody treatment for preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT) in pregnant women at higher risk for alloimmunization, according to study information posted recently on ClinicalTrials.gov.  RLYB212 has the potential to significantly reduce risks to both mothers and […]

• Non-invasive testing could help predict infant blood groups

  Non-invasive prenatal testing has enhanced safety and accuracy for alloimmunized pregnancies, including in those with FNAIT and HDFN.

• New hemolysis tests could improve safety of IVIG treatments

  In a recent study, functional assays more accurately assessed hemolysis risks in IVIG products, which are a frontline treatment in FNAIT.

• New therapy shows early promise in preventing FNAIT

  Preclinical data from Rallybio suggested that RLYB212 may prevent fetal and neonatal allo-immune thrombocytopenia in high-risk pregnancies.